Rituximab: a potential therapeutic advance in scleroderma: what is the evidence?

Rheumatology (Oxford). 2010 Feb;49(2):201-2. doi: 10.1093/rheumatology/kep421. Epub 2009 Dec 23.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • B-Lymphocytes / immunology
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Lymphocyte Depletion / methods
  • Rituximab
  • Scleroderma, Systemic / drug therapy*
  • Scleroderma, Systemic / immunology

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Immunosuppressive Agents
  • Rituximab